BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jahrsdörfer B, Fabricius D, Scholz J, Ludwig C, Grempels A, Lotfi R, Körper S, Adler G, Schrezenmeier H. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Front Immunol 2021;12:743422. [PMID: 34659239 DOI: 10.3389/fimmu.2021.743422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yaugel-Novoa M, Bourlet T, Paul S. Role of the humoral immune response during COVID-19: guilty or not guilty? Mucosal Immunol 2022;15:1170-80. [PMID: 36195658 DOI: 10.1038/s41385-022-00569-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mancuso R, Agostini S, Citterio LA, Chiarini D, Santangelo MA, Clerici M. Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. Vaccines (Basel) 2022;10:1649. [PMID: 36298514 DOI: 10.3390/vaccines10101649] [Reference Citation Analysis]
3 Gachoud D, Pillonel T, Tsilimidos G, Battolla D, Dumas D, Opota O, Fontana S, Vollenweider P, Manuel O, Greub G, Bertelli C, Rufer N. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. Br J Haematol 2022. [PMID: 36101920 DOI: 10.1111/bjh.18450] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Ishizaki A, Bi X, Nguyen QT, Maeno T, Hara A, Nakamura H, Kuramoto S, Nishi K, Ooe H, Ichimura H. Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan. PLoS ONE 2022;17:e0273712. [DOI: 10.1371/journal.pone.0273712] [Reference Citation Analysis]
5 Garnica M, Aiello A, Ligotti ME, Accardi G, Arasanz H, Bocanegra A, Blanco E, Calabrò A, Chocarro L, Echaide M, Kochan G, Fernandez-rubio L, Ramos P, Pojero F, Zareian N, Piñeiro-hermida S, Farzaneh F, Candore G, Caruso C, Escors D. How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells. IJMS 2022;23:9797. [DOI: 10.3390/ijms23179797] [Reference Citation Analysis]
6 Jahrsdörfer B, Proffen M, Scholz J, Hägele J, Ludwig C, Vieweg C, Grempels A, Fabricius D, Lotfi R, Körper S, Adler G, Schrezenmeier H. BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Front Immunol 2022;13:920210. [DOI: 10.3389/fimmu.2022.920210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Osmanodja B, Ronicke S, Budde K, Jens A, Hammett C, Koch N, Seelow E, Waiser J, Zukunft B, Bachmann F, Choi M, Weber U, Eberspächer B, Hofmann J, Grunow F, Mikhailov M, Liefeldt L, Eckardt KU, Halleck F, Schrezenmeier E. Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J Clin Med 2022;11:2565. [PMID: 35566691 DOI: 10.3390/jcm11092565] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
8 Gachoud D, Pillonel T, Gerasimos T, Battola D, Dumas D, Opota O, Fontana S, Vollenweider P, Manuel O, Greub G, Bertelli C, Rufer N. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agents.. [DOI: 10.1101/2022.04.24.22274200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Osmanodja B, Ronicke S, Budde K, Jens A, Hammett C, Koch N, Seelow E, Waiser J, Zukunft B, Bachmann F, Choi M, Weber U, Eberspächer B, Hofmann J, Grunow F, Mikhailov M, Liefeldt L, Eckardt K, Halleck F, Schrezenmeier E. Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients.. [DOI: 10.1101/2022.03.23.22270017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]